Brainomix US expansion gathers speed

Oxford-based AI-powered medtech solutions company Brainomix has announced its continued expansion in the US with the launch of its full suite of FDA-cleared modules in its Brainomix 360 platform for stroke care.

The US launch, which included its previously announced FDA cleared e-ASPECTS module, represents a comprehensive platform designed to support clinicians and their imaging-based treatment decisions at all points across the stroke pathway, from simple imaging to more advanced imaging.

This Brainomix 360 platform is powered by AI algorithms that provide real-time interpretation of brain scans to aid treatment and transfer decisions for stroke patients. The purpose is to quicken the process, meaning patients can get the right treatment at the right time.

Visit Hampshire Biz News for bright, upbeat and positive business news from the county

Brainomix has established commercial operations in the US and will continue to expand as it rolls out its products across US hospital networks.

Dr Michalis Papadakis, co-founder and CEO of Brainomix, said: “We are delighted to have the opportunity to introduce our Brainomix 360 platform to more and more US stroke networks, and to showcase the extensive validation of our technology, a good portion of which was conducted in the US at such institutions as the Mayo Clinic, Emory University, Mount Sinai in New York, and UCLA

“As a spin-out from the University of Oxford, we have a longstanding heritage of scientific and academic excellence, which has allowed us to achieve broad success in the UK and across Europe.

''This includes national-level deployments of Brainomix 360 across Hungary and Wales, as well as wide-ranging roll-outs in England, Poland, Sweden, Italy and Spain.”

Read more - NATS teams up with Saudi Air Navigation Services on airport capacity study